DTC drug debate

September 2008
Marketing Health Services;Fall2008, Vol. 28 Issue 3, p6
Academic Journal
The article reports that the Energy and Commerce Committee of the U.S. House of Representatives has pressured pharmaceutical companies to stop advertising their new drugs. William C. Weldon, chief executive officer (CEO) of drug company Johnson & Johnson, said his company would first discuss their new drugs with health professionals for six months before advertising directly to consumers. This information was first reported in the "Advertising Age" magazine in June, 2008.


Related Articles

  • Company Spotlight: Johnson & Johnson.  // MarketWatch: Global Round-up;Dec2007, Vol. 6 Issue 12, p106 

    The article reports on the increase of the sales of Johnson & Johnson in the third quarter of 2007. The growth was attributed to the strong performance of its pharmaceutical, medical devices and diagnostic division. Its consumer segments sales has generated a total of $3.6 billion and represents...

  • J&J Buys Online Health Coach. P., Shankar // njbiz;11/3/2008, Vol. 21 Issue 45, p2 

    The article reports on the purchase of HealthMedia Inc. in Ann Arbor, Michigan, by Johnson & Johnson (J&J) in New Brunswick, New Jersey. It states that HealthMedia, which calls itself an online health coach, runs programs sponsored by pharmaceutical companies that promote health, wellness and...

  • CORPORATE.  // MondayMorning;1/30/2012, Vol. 20 Issue 5, p2 

    This section offers news briefs on the pharmaceutical industry. Johnson & Johnson (J&J) Chief Executive Officer (CEO) William C. Weldon said the decline in medical spending may be ending. Abbott Laboratories of Illinois plans to lay off 700 employees as part of its restructuring efforts....

  • JOHNSON & JOHNSON INC.  // MondayMorning;1/26/2009, Vol. 17 Issue 3, p1 

    The article presents William Weldon statements, chief executive at Johnson & Johnson (J&J), about the company in the U.S. He says that it has a list of takeover targets and will at least take a look at deals involving big drugmakers. The excuitve mentions about the announcement made by J&J on...

  • Medical groups mum on DTC ads. Thomaselli, Rich // Advertising Age;2/25/2008, Vol. 79 Issue 8, p4 

    The article reports that influential organizations within the medical community, including the American Medical Association, the American College of Cardiology, and "New England Journal of Medicine" have yet to take a position on the direct marketing of prescription drugs to consumers. The U.S....

  • FROM THE K STREET CORRIDOR.  // National Journal;4/08/2000, Vol. 32 Issue 15, p1142 

    Presents news briefs on politics from around the world. Action taken by the pharmaceutical industry to challenge legislation that would bar companies from selling the prescription drugs at a higher price in the United States (US); Reaction of the Turkish government on a congressional resolution...

  • DTC advertising guidelines approved, welcomed in the US.  // PharmacoEconomics & Outcomes News;8/13/2005, Issue 484, p2 

    Reports on the approval of the "Guiding Principles" for direct-to-consumer (DTC) advertising of Pharmaceutical Research and Manufacturers of America (PhRMA) effective January 2006. Statement issued by PhRMA board chairman William C. Weldon about good DTC advertising; Pharmaceutical companies...

  • New Health Reform Bill Drops Ban on 'Pay-for-Delay' Deals. Young, Donna // BioWorld Today;3/19/2010, Vol. 21 Issue 53, p1 

    The article reports that a health care reform bill seeking a ban on pay-for-delay deals has been dropped by the U.S. House. The deals refer to settlements in which pharmaceutical firms pay genetic drugmakers to keep their products off the market. According to AstraZeneca plc chief executive...

  • Biopharma Seeks Escape From Regulatory Chokehold. Serebrov, Mari // BioWorld Today;7/30/2012, Vol. 23 Issue 146, p1 

    The article reports on the effort of the biopharmaceutical industry to pursue more financial reforms in the U.S. The effort aims at reducing bureaucracy that affects small biotechnology companies. Jeffrey Hatfield, president and chief executive officer (CEO) of Vitae Pharmaceuticals, testified...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics